Birchview Capital’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Birchview Capital’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-100,000	Closed	-$1.5M	–	59
2022 Q4	$1.5M	Sell	100,000 -40,000	-29%	-$554K	1.06%	17
2022 Q3	$1.15M	Hold	140,000	–	–	0.81%	24
2022 Q2	$918K	Hold	140,000	–	–	0.67%	23
2022 Q1	$783K	Hold	140,000	–	–	0.56%	32
2021 Q4	$657K	Buy	140,000 +100,000	+250%	+$620K	0.42%	39
2021 Q3	$247K	Buy	+40,000	New	+$239K	0.17%	56
2018 Q4	–	Sell	-12,000	Closed	-$397K	–	57
2018 Q3	$397K	Buy	12,000 +2,000	+20%	+$51.4K	0.26%	39
2018 Q2	$226K	Hold	10,000	–	–	0.15%	43
2018 Q1	$290K	Buy	+10,000	New	+$293K	0.19%	38

Birchview Capital's AVEO Position: Q1 2023 in Review

Birchview Capital sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 100,000 shares — an estimated $1.5M sold.

Birchview Capital first reported a position in AVEO in Q1 2018 and held it in 9 quarters. The position peaked at $1.5M in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.

Birchview Capital reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Birchview Capital sold 100,000 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $1.5M.
Birchview Capital first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2018 and held it in 9 quarters.
Birchview Capital's AVEO Pharmaceuticals, Inc. position peaked at $1.5M in Q4 2022.
0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.

Based on Birchview Capital's 13F filing for Q1 2023, filed 12 May 2023.